Clevegen
Clevegen is a novel immunotherapy drug designed to target and modulate the immune system to treat various forms of cancer. It is developed by Faron Pharmaceuticals, a clinical-stage biopharmaceutical company. Clevegen is an anti-Clever-1 antibody that works by blocking the Clever-1 receptor, which is involved in the suppression of the immune response against tumors.
Mechanism of Action[edit]
Clevegen functions by targeting the Clever-1 receptor, also known as Stabilin-1, which is expressed on the surface of certain immune cells, including macrophages. By inhibiting Clever-1, Clevegen reprograms these macrophages from a tumor-supportive (M2) phenotype to a tumoricidal (M1) phenotype. This shift enhances the body's immune response against cancer cells, promoting their destruction.
Clinical Development[edit]
Clevegen is currently undergoing clinical trials to evaluate its safety and efficacy in treating various types of cancer, including colorectal cancer, ovarian cancer, and pancreatic cancer. The drug has shown promise in early-phase trials, demonstrating the ability to modulate the immune system and reduce tumor growth.
Potential Applications[edit]
Clevegen's ability to modulate the immune system makes it a potential treatment for a wide range of cancers. It is being investigated both as a monotherapy and in combination with other treatments, such as chemotherapy and checkpoint inhibitors. The versatility of Clevegen could make it a valuable addition to the arsenal of cancer therapies.
Related Pages[edit]
- Faron Pharmaceuticals
- Immunotherapy
- Clever-1
- Macrophage
- Colorectal cancer
- Ovarian cancer
- Pancreatic cancer
- Chemotherapy
- Checkpoint inhibitors
See Also[edit]
Template:Immunotherapy-drug-stub
